49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00412841 (ClinicalTrials.gov) | November 2002 | 18/12/2006 | Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus | AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial | Avascular Necrosis | Drug: Atorvastatin;Procedure: MRI, Venipuncture;Drug: Placebo | NYU Langone Health | NULL | Terminated | 18 Years | 75 Years | Female | 43 | Phase 2 | United States |